Breaking News

Emergent BioSolutions Receives BioThrax Approval

German Federal Ministry of Health approves the company’s Michigan facility for large-scale manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Emergent BioSolutions said that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, has approved the company’s large-scale manufacturing facility, Building 55, located in Lansing, MI. This approval allows Emergent to market BioThrax (Anthrax Vaccine Adsorbed) manufactured in Building 55 in Germany. BioThrax is the only anthrax vaccine licensed by the PEI for pre-exposure prophylaxis of anthrax disease. It is also the only anthrax vaccine licensed b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters